| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 SEM Herman, AL Gordon, E Hertlein, A Ramanunni, X Zhang, ... Blood, The Journal of the American Society of Hematology 117 (23), 6287-6296, 2011 | 1032 | 2011 |
| CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability BJ Lannutti, SA Meadows, SEM Herman, A Kashishian, B Steiner, ... Blood, The Journal of the American Society of Hematology 117 (2), 591-594, 2011 | 887 | 2011 |
| Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival … SEM Herman, AL Gordon, AJ Wagner, NA Heerema, W Zhao, JM Flynn, ... Blood, The Journal of the American Society of Hematology 116 (12), 2078-2088, 2010 | 743 | 2010 |
| Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial MZH Farooqui, J Valdez, S Martyr, G Aue, N Saba, CU Niemann, ... The lancet oncology 16 (2), 169-176, 2015 | 497 | 2015 |
| Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia IE Ahn, C Underbayev, A Albitar, SEM Herman, X Tian, I Maric, DC Arthur, ... Blood, The Journal of the American Society of Hematology 129 (11), 1469-1479, 2017 | 375 | 2017 |
| Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL SEM Herman, RZ Mustafa, JA Gyamfi, S Pittaluga, S Chang, B Chang, ... Blood, The Journal of the American Society of Hematology 123 (21), 3286-3295, 2014 | 323 | 2014 |
| Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients BY Chang, M Francesco, MFM De Rooij, P Magadala, SM Steggerda, ... Blood, The Journal of the American Society of Hematology 122 (14), 2412-2424, 2013 | 257 | 2013 |
| Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib C Sun, X Tian, YS Lee, S Gunti, A Lipsky, SEM Herman, D Salem, ... Blood, The Journal of the American Society of Hematology 126 (19), 2213-2219, 2015 | 243 | 2015 |
| Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity HE Kohrt, I Sagiv-Barfi, S Rafiq, SEM Herman, JP Butchar, C Cheney, ... Blood, The Journal of the American Society of Hematology 123 (12), 1957-1960, 2014 | 243 | 2014 |
| Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study SEM Herman, CU Niemann, M Farooqui, J Jones, RZ Mustafa, A Lipsky, ... Leukemia 28 (11), 2188-2196, 2014 | 227 | 2014 |
| Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study CU Niemann, SEM Herman, I Maric, J Gomez-Rodriguez, A Biancotto, ... Clinical Cancer Research 22 (7), 1572-1582, 2016 | 223 | 2016 |
| Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study IE Ahn, MZH Farooqui, X Tian, J Valdez, C Sun, S Soto, J Lotter, S Housel, ... Blood, The Journal of the American Society of Hematology 131 (21), 2357-2366, 2018 | 222 | 2018 |
| Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib AH Lipsky, MZH Farooqui, X Tian, S Martyr, AM Cullinane, K Nghiem, ... Haematologica 100 (12), 1571, 2015 | 198 | 2015 |
| The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy DA Landau, C Sun, D Rosebrock, SEM Herman, J Fein, M Sivina, ... Nature communications 8 (1), 2185, 2017 | 195 | 2017 |
| Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia LA Andritsos, AJ Johnson, G Lozanski, W Blum, C Kefauver, F Awan, ... Journal of Clinical Oncology 26 (15), 2519-2525, 2008 | 178 | 2008 |
| Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals R Lapalombella, YY Yeh, L Wang, A Ramanunni, S Rafiq, S Jha, J Staubli, ... Cancer cell 21 (5), 694-708, 2012 | 177 | 2012 |
| The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia SEM Herman, A Montraveta, CU Niemann, H Mora-Jensen, M Gulrajani, ... Clinical Cancer Research 23 (11), 2831-2841, 2017 | 174 | 2017 |
| Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma NS Saba, D Liu, SEM Herman, C Underbayev, X Tian, D Behrend, ... Blood, The Journal of the American Society of Hematology 128 (1), 82-92, 2016 | 174 | 2016 |
| Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway R Lapalombella, L Andritsos, Q Liu, SE May, R Browning, LV Pham, ... Blood, The Journal of the American Society of Hematology 115 (13), 2619-2629, 2010 | 148 | 2010 |
| Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood TM Herndon, SS Chen, NS Saba, J Valdez, C Emson, M Gatmaitan, ... Leukemia 31 (6), 1340-1347, 2017 | 144 | 2017 |
